Peer-reviewed veterinary case report
Potential Therapeutic Effects ofMCC1274 on Alzheimer's Disease Pathologies inMice.
- Journal:
- Nutrients
- Year:
- 2024
- Authors:
- Abdelhamid, Mona et al.
- Affiliation:
- Department of Biochemistry · Japan
- Species:
- rodent
Abstract
We previously demonstrated that orally supplementedMCC1274 (MCC1274) mitigated Alzheimer's disease (AD) pathologies in both 7-month-oldmice and wild-type mice; thus,MCC1274 supplementation might potentially prevent the progression of AD. However, the possibility of using this probiotic as a treatment for AD remains unclear. Thus, we investigated the potential therapeutic effects of this probiotic on AD using 17-month-oldmice with memory deficits and amyloid beta saturation in the brain.MCC1274 supplementation ameliorated memory impairment via an amyloid-cascade-independent pathway. It reduced hippocampal and cortical levels of phosphorylated extracellular signal-regulated kinase and c-Jun-terminal kinase as well as heat shock protein 90, which might have suppressed tau hyperphosphorylation and chronic stress. Moreover,MCC1274 supplementation increased hippocampal synaptic protein levels and upregulated neuronal activity. Thus,MCC1274 supplementation may alleviate cognitive dysfunction by reducing chronic stress and tau hyperphosphorylation, thereby enhancing both synaptic density and neuronal activity in 17-month-oldmice. Overall, this study suggests thatMCC1274 has anti-AD effects and can be used as a potential treatment for AD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/38398861/